126 related articles for article (PubMed ID: 35344906)
1. Corrigendum to "Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity" [Eur. J. Med. Chem. 122 (2016) 232-246].
Gaura R; Pathania AS; Malik FA; Bhakuni RS; Verma RK
Eur J Med Chem; 2022 May; 235():114277. PubMed ID: 35344906
[No Abstract] [Full Text] [Related]
2. Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.
Gaur R; Pathania AS; Malik FA; Bhakuni RS; Verma RK
Eur J Med Chem; 2016 Oct; 122():232-246. PubMed ID: 27371926
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors" [Eur. J. Med. Chem. 197 (2020) 112308].
Shuai W; Li X; Li W; Xu F; Lu L; Yao H; Yang L; Zhu H; Xu S; Zhu Z; Xu J
Eur J Med Chem; 2020 Aug; 200():112464. PubMed ID: 32512484
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Design, synthesis, DFT study and antifungal activity of the derivatives of pyrazolecarboxamide containing thiazole or oxazole ring" [Eur. J. Med. Chem. 149 (2018) 170-181].
Yan Z; Liu A; Huang M; Liu M; Pei H; Huang L; Yi H; Liu W; Hu A
Eur J Med Chem; 2018 May; 152():392. PubMed ID: 29747120
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].
Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
Eur J Med Chem; 2016 Nov; 124():248. PubMed ID: 27592393
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
Ge H; Zhang W; Yuan K; Xue H; Cheng H; Chen W; Xie Y; Zhang J; Xu X; Yang P
Eur J Med Chem; 2022 Jan; 228():114041. PubMed ID: 34902733
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].
Li ZH; Zhao TQ; Liu XQ; Zhao B; Wang C; Geng PF; Cao YQ; Fu DJ; Jiang LP; Yu B; Liu HM
Eur J Med Chem; 2019 Nov; 181():111387. PubMed ID: 31376565
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Design and synthesis of novel artemisinin hybrids with potent activities against human colorectal cancer cells in vitro and in vivo" [Eur. J. Med. Chem. 182 (2019) 111665].
Wang LL; Kong L; Liu H; Zhang Y; Zhang L; Liu X; Yuan F; Li Y; Zuo Z
Eur J Med Chem; 2020 May; 194():112256. PubMed ID: 32220686
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease" [Eur. J. Med. Chem. 163 (2019), 307-319. DOI: 10.1016/j.ejmech.2018.11.040].
Tang YW; Shi CJ; Yang HL; Cai P; Liu QH; Yang XL; Kong LY; Wang XB
Eur J Med Chem; 2024 Jun; ():116591. PubMed ID: 38890013
[No Abstract] [Full Text] [Related]
14. Corrigendum to "New desulfured troglitazone derivatives: Improved synthesis and biological evaluation" [Eur. J. Med. Chem. 187 (2020) 111939].
Dupommier D; Muller C; Comoy C; Mazerbourg S; Bordessa A; Piquard E; Pawlak M; Piquard F; Martin H; De Fays E; Grandemange S; Flament S; Boisbrun M
Eur J Med Chem; 2020 Dec; 208():112834. PubMed ID: 32966897
[No Abstract] [Full Text] [Related]
15. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents" [Eur. J. Med. Chem. 162 (162) (2019) 203-211].
Su L; Li J; Zhou Z; Huang D; Zhang Y; Pei H; Guo W; Wu H; Wang X; Liu M; Yang CG; Chen Y
Eur J Med Chem; 2019 Apr; 168():385. PubMed ID: 30826513
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
[No Abstract] [Full Text] [Related]
18. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
Poratti M; Marzaro G
Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
[No Abstract] [Full Text] [Related]
20. Corrigendum to 'Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-b1 pathway' [Eur. J. Med. Chem. 157 (2018) 229-247].
Li X; Lu C; Liu S; Liu S; Su C; Xiao T; Bi Z; Sheng P; Huang M; Liu X; Wei Y; Zhao L; Miao S; Mao J; Huang K; Gao S; Liu N; Qi M; Liu T; Qin S; Wei L; Sun T; Ning W; Yang G; Zhou H; Yang C
Eur J Med Chem; 2019 Feb; 163():403. PubMed ID: 30530191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
